NanoViricides' FluCide narcotic aspirant greatly reduces lung viral worry in animals

NanoViricides, Inc. (OTCBB: NNVC.OB) (the Company) reports that post-infection treatment with its optimized FluCideâ„¢ hypnotic candidates achieved 1,000-fold reduction in the levels of contagious virus in the lungs of animals with a lethal au fait with of influenza virus infection. These findings corroborate the previously reported findings of both increased animal survival and protection of the lungs from influenza virus mass bill in FluCide-treated animals in the most just out H1N1 influenza study.

The amount of contagious virus in the lungs of the infected animals treated with three of the optimized FluCide™ nanoviricide painkiller Buy VPXL candidates was reduced close to greater than 1000-fold as compared to the infected untreated manage animals (p-values 0.001), four days after virus infection. In dissimilarity, animals treated with Oseltamivir (Tamiflu®, Roche) showed less than a 2-fold reducti on in lung viral encumbrance at the having said that time point. This indicated a 500-fold greater reduction in viral worry next to FluCide antidepressant candidates to Oseltamivir.

Of great clinical connotation is the fact that 2 of the optimized FluCide™ pharmaceutical candidates maintained this greatly reduced lung viral overwhelm at 7, 13 and 19 days after virus infection in this 21 epoch study. Thus, treatment with FluCide drug candidates appeared to defend against the finished sequence of infection, virus bourgeoning and spread of infection in the lungs that follows the initial virus infection. This was not the invalid for the purpose the oseltamivir-treated animals. Animals treated with Oseltamivir (Tamiflu®, Roche) showed less than a 2-fold reduction in lung viral load at 4 days and the viral weight was increased at 7 days to the for all that straightforward as that develop in the infected, untreated rule animals in a little while beforehand their death.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Trait A/WS/33 (H1N1) were aspirated without delay into the lungs of mice. The constant amount of virus infection was repeated at 22 hrs. This influenza perfect was designed to be uniformly decreed in 100% of the infected, untreated animals within 5 days after infection. Treatment with the FluCide candidates and Oseltamivir commenced 24 hours after the oldest viral infection. The duration of the cram was 21 days.

The Company has beforehand reported that the uniform optimized FluCideâ„¢ nanoviricide medication candidates achieved significantly increased survival (20.2 to 22.2 days) and greater than 95% reduction in lung redness and necrosis in this study. In diverge, animals treated with Oseltamivir showed a mean survival of just 8.3 days and alone a 50% reduction in lung inflammation and necrosis.

The dramatic reduction in the order strattera 25mg transmissible viral pressure obviously establishes that we obtain unusually noticeable, direct-acting, antiviral downer candidates, said Dr. Randall Barton, Chief Well-controlled Officer of the Company.

Such a heady viral load reduction would enable temperate bird-flu infected patients to retrieve pronto, assuming these results take in humans, said Eugene Seymour, MD, MPH, CEO of the Company.